Bicycle Therapeutics (BCYC) Competitors

$4.55 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.54 -0.01 (-0.22%)

As of 05/22/2026 04:41 PM Eastern

BCYC vs. GHRS, CRVS, OLMA, MAZE, and CMPS

Should you buy Bicycle Therapeutics stock or one of its competitors? MarketBeat compares Bicycle Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicycle Therapeutics include GH Research (GHRS), Corvus Pharmaceuticals (CRVS), Olema Pharmaceuticals (OLMA), Maze Therapeutics (MAZE), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.

How does Bicycle Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

GH Research currently has a consensus target price of $40.38, suggesting a potential upside of 82.53%. Bicycle Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 207.69%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

GH Research has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. GH Research's return on equity of -19.36% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

GH Research has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

GH Research has higher earnings, but lower revenue than Bicycle Therapeutics. GH Research is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Bicycle Therapeutics	$72.86M	4.35	-$218.96M	-$3.15	N/A

In the previous week, GH Research had 8 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 9 mentions for GH Research and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.00 beat GH Research's score of -0.86 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.9% of GH Research shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

GH Research beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Bicycle Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Bicycle Therapeutics	$72.86M	4.35	-$218.96M	-$3.15	N/A

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 164.34%. Bicycle Therapeutics has a consensus price target of $14.00, indicating a potential upside of 207.69%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Corvus Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Corvus Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Corvus Pharmaceuticals had 12 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 13 mentions for Corvus Pharmaceuticals and 1 mentions for Bicycle Therapeutics. Corvus Pharmaceuticals' average media sentiment score of 0.14 beat Bicycle Therapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bicycle Therapeutics beats Corvus Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Olema Pharmaceuticals?

Bicycle Therapeutics (NASDAQ:BCYC) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Bicycle Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 207.69%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 222.37%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Olema Pharmaceuticals has lower revenue, but higher earnings than Bicycle Therapeutics. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.35	-$218.96M	-$3.15	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Bicycle Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

Olema Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Olema Pharmaceuticals had 6 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 7 mentions for Olema Pharmaceuticals and 1 mentions for Bicycle Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.19 beat Bicycle Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Olema Pharmaceuticals beats Bicycle Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Maze Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

In the previous week, Maze Therapeutics had 22 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 23 mentions for Maze Therapeutics and 1 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.00 beat Maze Therapeutics' score of -0.68 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Bicycle Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

Maze Therapeutics has higher revenue and earnings than Bicycle Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.35	-$218.96M	-$3.15	N/A
Maze Therapeutics	$167.50M	8.52	-$131.12M	-$2.53	N/A

Bicycle Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 207.69%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 156.01%. Given Bicycle Therapeutics' higher possible upside, research analysts plainly believe Bicycle Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Maze Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Maze Therapeutics	N/A	-36.62%	-31.78%

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Maze Therapeutics beats Bicycle Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Compass Pathways presently has a consensus price target of $20.58, indicating a potential upside of 74.29%. Bicycle Therapeutics has a consensus price target of $14.00, indicating a potential upside of 207.69%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Compass Pathways has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Compass Pathways' return on equity of -31.07% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

In the previous week, Compass Pathways had 12 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 13 mentions for Compass Pathways and 1 mentions for Bicycle Therapeutics. Compass Pathways' average media sentiment score of 0.60 beat Bicycle Therapeutics' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bicycle Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Bicycle Therapeutics	$72.86M	4.35	-$218.96M	-$3.15	N/A

Compass Pathways has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Summary

Compass Pathways beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCYC vs. The Competition

Export

Metric	Bicycle Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$317.18M	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.44	18.91	21.00	25.66
Price / Sales	4.35	329.35	615.84	111.99
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.57	7.09	10.37	7.14
Net Income	-$218.96M	$24.45M	$3.57B	$335.98M
7 Day Performance	4.36%	5.45%	6.00%	3.56%
1 Month Performance	-5.99%	2.43%	3.51%	2.54%
1 Year Performance	-43.48%	62.98%	34.12%	35.05%

Bicycle Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCYC Bicycle Therapeutics	3.0531 of 5 stars	$4.55 flat	$14.00 +207.7%	-43.5%	$317.18M	$72.86M	N/A	240	News Coverage Gap Down
GHRS GH Research	2.8973 of 5 stars	$21.26 -0.7%	$40.13 +88.7%	+98.0%	$1.33B	N/A	N/A	10	Gap Up
CRVS Corvus Pharmaceuticals	2.3527 of 5 stars	$15.81 +1.7%	$33.33 +110.8%	+261.3%	$1.31B	N/A	N/A	30	Gap Up
OLMA Olema Pharmaceuticals	2.5262 of 5 stars	$14.86 -0.3%	$44.40 +198.8%	+171.4%	$1.30B	N/A	N/A	70	Analyst Forecast
MAZE Maze Therapeutics	2.1475 of 5 stars	$25.52 -2.0%	$66.00 +158.6%	+150.8%	$1.30B	N/A	N/A	121	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. GHRS, CRVS, OLMA, MAZE, and CMPS

How does Bicycle Therapeutics compare to GH Research?

Summary

How does Bicycle Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Bicycle Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Bicycle Therapeutics compare to Maze Therapeutics?

Summary

How does Bicycle Therapeutics compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. GHRS, CRVS, OLMA, MAZE, and CMPS

How does Bicycle Therapeutics compare to GH Research?

Do analysts prefer GHRS or BCYC?

Is GHRS or BCYC more profitable?

Which has more volatility and risk, GHRS or BCYC?

Which has stronger earnings & valuation, GHRS or BCYC?

Does the media refer more to GHRS or BCYC?

Do institutionals & insiders hold more shares of GHRS or BCYC?

Summary

How does Bicycle Therapeutics compare to Corvus Pharmaceuticals?

Which has stronger earnings and valuation, CRVS or BCYC?

Do analysts recommend CRVS or BCYC?

Is CRVS or BCYC more profitable?

Which has more volatility and risk, CRVS or BCYC?

Do institutionals and insiders have more ownership in CRVS or BCYC?

Does the media refer more to CRVS or BCYC?

Summary

How does Bicycle Therapeutics compare to Olema Pharmaceuticals?

Do analysts recommend BCYC or OLMA?

Which has stronger earnings and valuation, BCYC or OLMA?

Which has more volatility & risk, BCYC or OLMA?

Is BCYC or OLMA more profitable?

Do institutionals & insiders believe in BCYC or OLMA?

Does the media prefer BCYC or OLMA?

Summary

How does Bicycle Therapeutics compare to Maze Therapeutics?

Does the media prefer BCYC or MAZE?

Which has more volatility & risk, BCYC or MAZE?

Which has better valuation and earnings, BCYC or MAZE?

Do analysts rate BCYC or MAZE?

Is BCYC or MAZE more profitable?

Do insiders and institutionals have more ownership in BCYC or MAZE?

Summary

How does Bicycle Therapeutics compare to Compass Pathways?

Do analysts prefer CMPS or BCYC?

Is CMPS or BCYC more profitable?

Does the media prefer CMPS or BCYC?

Do insiders & institutionals have more ownership in CMPS or BCYC?

Which has stronger earnings and valuation, CMPS or BCYC?

Which has more volatility & risk, CMPS or BCYC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools